PL3466934T3 - Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu - Google Patents

Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu

Info

Publication number
PL3466934T3
PL3466934T3 PL17806708.8T PL17806708T PL3466934T3 PL 3466934 T3 PL3466934 T3 PL 3466934T3 PL 17806708 T PL17806708 T PL 17806708T PL 3466934 T3 PL3466934 T3 PL 3466934T3
Authority
PL
Poland
Prior art keywords
salt
treating cancer
reductase inhibitors
ribonucleotide reductase
sulfonamide compounds
Prior art date
Application number
PL17806708.8T
Other languages
English (en)
Inventor
Seiji Miyahara
Hiroyuki Ueno
Shoki HARA
Yoshio Ogino
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3466934T3 publication Critical patent/PL3466934T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17806708.8T 2016-05-31 2017-05-30 Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu PL3466934T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016109609 2016-05-31
PCT/JP2017/020166 WO2017209155A1 (ja) 2016-05-31 2017-05-30 スルホンアミド化合物又はその塩

Publications (1)

Publication Number Publication Date
PL3466934T3 true PL3466934T3 (pl) 2024-06-10

Family

ID=60478546

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17806708.8T PL3466934T3 (pl) 2016-05-31 2017-05-30 Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu

Country Status (21)

Country Link
US (1) US11634395B2 (pl)
EP (1) EP3466934B1 (pl)
JP (1) JP6532607B2 (pl)
KR (2) KR102543559B1 (pl)
CN (1) CN109563057B (pl)
AU (1) AU2017275209C1 (pl)
CA (1) CA3025887C (pl)
DK (1) DK3466934T3 (pl)
ES (1) ES2982299T3 (pl)
FI (1) FI3466934T3 (pl)
HU (1) HUE067028T2 (pl)
MA (1) MA45185A (pl)
MX (1) MX385269B (pl)
MY (1) MY194676A (pl)
PH (1) PH12018502513A1 (pl)
PL (1) PL3466934T3 (pl)
PT (1) PT3466934T (pl)
RU (1) RU2732572C2 (pl)
SG (1) SG11201810704WA (pl)
TW (1) TWI746562B (pl)
WO (1) WO2017209155A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3466934T3 (pl) 2016-05-31 2024-06-10 Taiho Pharmaceutical Co., Ltd. Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu
MA51228A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
MA51224A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Composés de sulfonamide et leur utilisation
EP3887357A1 (en) 2018-11-28 2021-10-06 Basf Se Pesticidal compounds
CN109608352A (zh) * 2018-12-28 2019-04-12 凯瑞斯德生化(苏州)有限公司 一种2,6-二甲基-l-酪氨酸的制备方法
CN110066308B (zh) * 2019-04-26 2022-05-27 上海药明康德新药开发有限公司 用于DNA编码化合物库构建中的On-DNA磺酰胺类化合物的合成方法
EP3978017A4 (en) * 2019-05-29 2023-06-28 Taiho Pharmaceutical Co., Ltd. Combination cancer therapy using sulfonamide compound and immunomodulatory
EP4143167B1 (en) 2020-04-28 2024-05-15 Basf Se Pesticidal compounds
WO2022187200A1 (en) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
WO2023043938A1 (en) * 2021-09-17 2023-03-23 Boundless Bio, Inc. Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
KR20240101555A (ko) * 2021-09-17 2024-07-02 바운드리스 바이오, 인크. 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
CN117024616B (zh) * 2023-07-10 2025-01-21 张琦 一种褐藻多糖衍生物纳米胶束的制备及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6689762B1 (en) * 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
AU1182300A (en) * 1998-11-17 2000-06-05 Fuji Photo Film Co., Ltd. Bisaryl compounds and cancer remedies containing the same
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
AU2001255796A1 (en) 2000-05-02 2001-11-12 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
IL154688A0 (en) 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
AU2003257170B2 (en) * 2002-08-09 2008-12-11 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP1798226A4 (en) * 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd TRAIZOL DERIVATIVE
TW200637870A (en) * 2005-01-31 2006-11-01 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound and salt thereof
TW200736234A (en) * 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
RU2409570C2 (ru) * 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
KR20100031528A (ko) * 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
WO2009023509A2 (en) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
CA2741974A1 (en) 2008-11-11 2010-05-20 Novartis Ag Salts of fingolimod
TW201120027A (en) 2009-12-11 2011-06-16 Exelixis Inc TGR5 agonists
US20130005678A1 (en) 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
PL3466934T3 (pl) 2016-05-31 2024-06-10 Taiho Pharmaceutical Co., Ltd. Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
MA51228A (fr) 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
MA51224A (fr) 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Composés de sulfonamide et leur utilisation

Also Published As

Publication number Publication date
RU2732572C2 (ru) 2020-09-21
WO2017209155A1 (ja) 2017-12-07
KR20210093395A (ko) 2021-07-27
TW201800395A (zh) 2018-01-01
PT3466934T (pt) 2024-04-30
RU2018145761A3 (pl) 2020-07-10
MA45185A (fr) 2019-04-10
FI3466934T3 (fi) 2024-04-23
KR102543559B1 (ko) 2023-06-13
US20200399235A1 (en) 2020-12-24
CN109563057A (zh) 2019-04-02
AU2017275209C1 (en) 2020-01-23
CN109563057B (zh) 2022-06-24
AU2017275209B2 (en) 2019-10-03
KR102311737B1 (ko) 2021-10-12
MX2018014762A (es) 2019-04-25
EP3466934A1 (en) 2019-04-10
JP6532607B2 (ja) 2019-06-19
AU2017275209A1 (en) 2019-01-17
CA3025887C (en) 2022-06-28
PH12018502513A1 (en) 2019-10-21
MY194676A (en) 2022-12-13
RU2018145761A (ru) 2020-07-10
MX385269B (es) 2025-03-14
BR112018074646A2 (pt) 2019-03-06
HUE067028T2 (hu) 2024-09-28
KR20190015731A (ko) 2019-02-14
CA3025887A1 (en) 2017-12-07
EP3466934A4 (en) 2019-12-11
DK3466934T3 (da) 2024-04-15
SG11201810704WA (en) 2018-12-28
ES2982299T3 (es) 2024-10-15
TWI746562B (zh) 2021-11-21
EP3466934B1 (en) 2024-03-27
US11634395B2 (en) 2023-04-25
JPWO2017209155A1 (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
PL3466934T3 (pl) Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu
IL281537A (en) EGFR inhibitor compounds
ZA201807766B (en) Macrocyclic mcl1 inhibitors for treating cancer
IL263178A (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL253945A0 (en) kdm1a inhibitors to treat the disease
SG11201708861VA (en) Methods for treating cancer
LT3377516T (lt) Kompozicija vėžiui gydyti
IL278247B (en) mct4 inhibitors to treat the disease
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
IL259773A (en) Mat2a inhibitors for treating mtap null cancer
EP3268087A4 (en) METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
EP3164394A4 (en) Gls1 inhibitors for treating disease
GB201709402D0 (en) Compounds for treating t-pll
IL255022A0 (en) Cancer treatment methods
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL255018A0 (en) Cancer treatment methods
IL255016A0 (en) Cancer treatment methods
EP3303289A4 (en) Compounds and methods for treating cancer
EP3296294A4 (en) Compound for treating or preventing breast cancer
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
HK40009735A (zh) 普利多匹定用於治疗肌张力障碍的用途
ZA201603748B (en) Direct reduction of diamminedichloropalladium (ii) salt
GB201613945D0 (en) Compounds useful as kinase inhibitors